Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study-Reference-Cited by-同舟云学术

Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study

Published:2020-09 Issue: Volume:128 Page:43-51
ISSN:0022-3956
Container-title:Journal of Psychiatric Research
language:en
Short-container-title:Journal of Psychiatric Research

Author:

Kamiya Makoto,Sabia Helene D.,Marella Julie,Fava Maurizio,Nemeroff Charles B.,Umeuchi Hideo,Iijima Michihiko,Chaki Shigeyuki,Nishino Izumi

Funder

Taisho Pharmaceutical R&D Inc.

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference44 articles.

1. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation;Aguilera;Regul. Pept.,2000

2. Diagnostic and Statistical Manual for Mental Disorders;American Psychiatric Association,2013

3. DSM-III-R Psychotic Disorders: procedural validity of the M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.). Concordance and causes for discordance with CIDI;Amorim;Eur. Psychiatr.,1998

4. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants;Berman;CNS Spectr.,2009

5. RESEARCH: validation of the Massachusetts general hospital antidepressant treatment history Questionnaire (ATRQ);Chandler;CNS Neurosci. Ther.,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melanin-concentrating hormone receptor: A therapeutic target for novel anxiolytics;Pharmacology Biochemistry and Behavior;2024-09

2. Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point;Pharmacopsychiatry;2024-08-19

3. Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention;Psychiatry and Clinical Neurosciences;2024-06-25

4. Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder;Expert Opinion on Emerging Drugs;2024-05-08

5. The HPA Axis as Target for Depression;Current Neuropharmacology;2024-05